ceftriaxone 500-mg

Phase 3

NNational Taiwan University Hospital

ceftriaxone 500-mg is one of 9 therapeutic programs targeting Gonorrhea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

GonorrheaRecruiting

GonorrheaPhase 3

Recruiting

Competition

Competitive Landscape

9 competitors in Gonorrhea

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

—2

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 3

Garamycin

SSchering-Plough

Approved

1 4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Factive

1 7

ceftriaxone 500-mg

NNational Taiwan University Hospital

Phase 3

1 8

Menacwy Liquid

GSK

Preclinical

1 9

Trumenba

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Gonorrhea

NCT07710118

Clinical

Trials by Indication[1]

Gonorrhea1 trial

500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection: A Noninferiority Randomized Controlled Trial

Recruiting·NNational Taiwan University Hospital·Phase 3·NCT07710118·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ceftriaxone 500-mg. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ceftriaxone 500-mg. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNational Taiwan University Hospital

ceftriaxone 500-mg

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Gonorrhea1 trial

References

Drug Info

Quick Facts

Related News